Biolinq announced today it secured $100m in a Series C funding round, the proceeds of which will be used to support regulatory clearance of its wearable patch for people with type 2 diabetes not using insulin and to drive manufacturing as well as commercialization efforts with partners, CEO Rich Yang told Medtech Insight.
San Diego-based Biolinq is developing a wearable patch that uses tiny microsensors that insert themselves to measure glucose just beneath the skin’s surface. That sets the technology apart from currently...
Key Takeaways
- Biolinq has secured $100 million in Series C funding to support FDA clearance, scale up manufacturing, and prepare for commercialization of its needle-free wearable glucose...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?